Menopausal metabolic syndrome (MMS) is a risk factor for cardiovascular disease in postmenopausal women due to estrogen deficiency that triggers the endothelial dysfunction and atherogenesis. The main MMC manifestations are abdominal obesity, dyslipidemia and carbohydrate metabolism disorders. The magnesium deficiency plays on of the most important roles in the pathogenesis of glucose intolerance, diabetes and coronary heart disease (CHD). Menopausal hormone therapy (MHT) is an important method of coronary heart disease preventing in postmenopausal women. The magnesium deficiency correction can significantly improve the  life quality in these patients.